Publication date: 04/07/2018
Mithra Pharmaceuticals SA/NV (Euronext Brussels: MITRA) today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Mr. François Fornieri, on 02 July 2018.
Mr. François Fornieri has notified Mithra that it has dropped below the 30% threshold on June 4 2018, following the capital increase by means of a private placement launched on May 30 2018. Mr. François Fornieri now holds 28.18% (10,606,757 shares) of the 37,639,495 shares currently outstanding. Previously, Mr. François Fornieri held 30.33% of the 34,967,579 shares outstanding.
At the time of Mr. François Fornieri’s last transparency declaration, he was holding Mithra Pharmaceutical’s shares in both his own name as well as through Mithra Participations (‘civil corporation’). As of 21 December 2016, this company has been dissolved. Each shareholder of Mithra Participations, including Mr. François Fornieri, has thus directly received part of the shares of Mithra Pharmaceuticals SA held by this company. However, Mr. François Fornieri did not cross any notification threshold at that occasion. It is only pursuant to the capital increase which took place in June 2018 that Mr. François Fornieri has passively dropped down below the 30% threshold. Indeed, as Mr. François Fornieri did not subscribe to the capital increase, he has been subject to dilution.
The detailed transparency notifications are available on the Investors website of Mithra (investors.mithra.com). An updated overview of the Mithra’s large shareholdings will be included in the corporate governance charter of Mithra, which will be made available on its website.
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead
development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a
complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com